← Back to Search

Cannabinoid

5 mg THC for Drunk Driving

Phase 1

Waitlist Available

Led By Dustin C Lee, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-administration, post-administration, 2, 4 hours

Awards & highlights

Study Summary

This trial aims to see how well eye movements can detect impairment from THC, whether previous cannabis use affects this, and how it relates to attention span. They will give different doses of THC to frequent and

Who is the study for?

This trial is for frequent and infrequent cannabis users to study how THC affects eye movements and attention. Participants must be able to consume THC and perform tasks that test their oculomotor function and sustained attention.Check my eligibility

What is being tested?

The study tests the effects of different doses of THC (0, 5mg, 30mg) on eye movement control and concentration in both regular and occasional cannabis users using a double-blind, placebo-controlled crossover design.See study design

What are the potential side effects?

Possible side effects from THC may include altered sensory perceptions, mood changes, difficulty with thinking or problem-solving, impaired memory, coordination issues, anxiety or paranoia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-administration, post-administration, 2, 4 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-administration, post-administration, 2, 4 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-administration, post-administration, 2, 4 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Commission Errors

Omission Errors

Reaction Time

+2 more

Secondary outcome measures

Antisaccade

Memory-Guided

Saccade Speed

+1 more

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: 5 mg THCExperimental Treatment1 Intervention

Inhaled cannabis - 5 mg THC

Group II: 30 mg THCExperimental Treatment1 Intervention

Inhaled cannabis - 30 mg THC

Group III: 0 mg THCPlacebo Group1 Intervention

Inhaled Cannabis - 0 mg THC

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cannabis

2014

Completed Phase 3

~810

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,599 Total Patients Enrolled

Johns Hopkins UniversityLead Sponsor

2,267 Previous Clinical Trials

14,837,522 Total Patients Enrolled

Dustin C Lee, PhDPrincipal InvestigatorJohns Hopkins University

1 Previous Clinical Trials

50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I meet the requirements to be considered as a potential candidate for this medical study?

"To be considered for enrollment in this study, individuals must have a history of alcohol abuse and fall within the age range of 18 to 60 years. The trial aims to recruit a total of 40 participants."

Answered by AI

Is the ongoing medical study actively seeking participants at this time?

"As per clinicaltrials.gov, the current status of this particular trial indicates that patient recruitment is not ongoing. This study was first displayed on August 1st, 2024 and its most recent update was made on April 5th, 2024. Despite the lack of open slots for participants in this trial at present, it's noteworthy that there are a significant number of 780 other trials actively seeking eligible candidates."

Answered by AI

Is the trial open to individuals under the age of 80?

"Recruitment for this study is targeting individuals over 18 years of age but under the age of 60."

Answered by AI

Has the FDA given its approval for a 5 mg dose of THC?

"Our team at Power rates the safety of 5 mg THC as a 1 on our scale. This rating is attributed to the limited safety and efficacy data available for this Phase I trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

2024. "Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06351540.

All > Cannabis